Clinical Trials in Tennessee

Showing 12581-12600 of 20,239 trials

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

NCT01324323

The purpose of this study is to evaluate the effect and safety of multiple doses of rifampin on the pharmacokinetics of romidepsin after a single intravenous (IV) infusion.

Hematologic MalignancyMalignant Lymphoma

Celgene14 participantsStarted Apr 2011

Sarasota, Florida, United States • Nashville, Tennessee, United States • London, United Kingdom

TERMINATEDPhase 229 miles

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

NCT02787304

The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).

Non-Alcoholic Steatohepatitis

Mirum Pharmaceuticals, Inc.197 participantsStarted Oct 2016

Coronado, California, United States • Fresno, California, United States • Los Angeles, California, United States +62 more locations

Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

Find Trials by Condition in Tennessee

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Diarrhea Predominant Irritable Bowel Syndrome in Females

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®

A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma

LegDeb2 Global Registry for Use of Legflow in Peripheral Arteries